DAN RODEN, MD
Osteopathic Medicine in Nashville, TN

2003016, Sep 4, 2003

Jun 8, 2001

09/877586

Dan Roden - Nashville TN, US
Sabina Kupershmidt - Nashville TN, US

A61B005/046

600/518000

An animal model of atrial fibrillation and a method of identifying an animal exhibiting an atrial fibrillation phenotype. The method includes providing an animal having a minK (-/-) genotype; recording electrocardiograms from the animal over an extended time period; and identifying an atrial fibrillation pattern in the electrocardiograms to thereby identify the animal as exhibiting an atrial fibrillation phenotype. A method of screening candidate substances for activity in the treatment of atrial fibrillation using an animal model is also disclosed, as is a method of treating atrial fibrillation using a candidate compound identified as having activity in the treatment of atrial fibrillation.

6458542, Oct 1, 2002

Oct 4, 2000

09/679185

Dan M. Roden - Nashville TN

Vanderbilt University - Nashville TN

C12Q 168

435 6, 435 912, 536 235, 536 2431, 536 2433

Isolated polynucleotide molecules, and peptides encoded by these molecules, are used in the analysis of human cardiac potassium channel minK subunit variants, as well as in screening and diagnostic applications relating to a D85N polymorphism in the KCNE1 gene encoding the human cardiac potassium channel minK subunit polypeptide. By analyzing biological samples from a subject, it is possible to type a human cardiac potassium channel minK subunit with regard to the KCNE1-D85N polymorphism, for example, in the context of screening for susceptibility to drug-induced cardiac arrhythmias.

2003010, Jun 12, 2003

Sep 30, 2002

10/260861

Alfred George - Brentwood TN, US
Dan Roden - Nashville TN, US

C12Q001/68, C12P019/34

435/006000, 435/091200

Isolated polynucleotide molecules, and peptides encoded by these molecules, are used in the analysis of human cardiac potassium channel minK subunit variants, as well as in screening and diagnostic applications relating to a D85N polymorphism in the KCNE1 gene encoding the human cardiac potassium channel minK subunit polypeptide. By analyzing biological samples from a subject, it is possible to type a human cardiac potassium channel minK subunit with regard to the KCNE1-D85N polymorphism, for example, in the context of screening for susceptibility to drug-induced cardiac arrhythmias.

2003001, Jan 16, 2003

Oct 30, 2001

10/000151

Jeffrey Balser - Brentwood TN, US
Alfred George - Brentwood TN, US
Dan Roden - Nashville TN, US

G01N033/567, C12Q001/68, C12P021/02, C12N005/06, C12N015/85

435/007210, 435/006000, 435/455000, 435/325000

The present invention discloses methods relating to screening methods and methods of identifying a compound that can modulate HERG potassium channel activity. The methods generally employ at least HERG and KCR1 polypeptides. The disclosed methods can be applied in the development of a candidate pharmaceutical or they can be employed to evaluate presently marketed pharmaceuticals.